anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Study 3 was a randomized, double-blind, placebo-controlled clinical trial in patients with primary progressive multiple sclerosis (PPMS) (NCT01194570). Patients were randomized 2:1 to receive either intravenous ocrelizumab 600 mg or placebo as two 300 mg intravenous infusions 2 weeks apart every 24 weeks for at least 120 weeks. Selection criteria required a baseline EDSS of 3 to 6.5 and a score of 2 or greater for the EDSS pyramidal functional system due to lower extremity findings. Neurological assessments were conducted every 12 weeks. An MRI scan was obtained at baseline and at Weeks 24, 48, and 120.

In Study 3, the primary outcome was the time to onset of disability progression attributable to MS confirmed to be present at the next neurological assessment at least 12 weeks later. Disability progression occurred when the EDSS score increased by 1 point or more from the baseline EDSS if the baseline EDSS was 5.5 points or less, or by 0.5 points or more if the baseline EDSS was more than 5.5 points. In Study 3, confirmed disability progression also was deemed to have occurred if patients who had onset of disability progression discontinued participation in the study before the next assessment. Additional outcome measures included timed 25-foot walk, and percentage change in T2 hyperintense lesion volume.

Study 3 randomized 488 patients to intravenous ocrelizumab and 244 to placebo; 21% of intravenous ocrelizumab-treated patients and 34% of placebo-treated patients did not complete the trial. The baseline demographic and disease characteristics were balanced between the two treatment groups. At baseline, the mean age of patients was 45; 49% were female. The mean time since symptom onset was 6.7 years, the mean EDSS score was 4.7, and 26% had one or more T1 Gd-enhancing lesions at baseline; 88% of patients had not been treated previously with a non-steroid treatment for MS. The time to onset of disability progression confirmed at 12 weeks after onset was significantly longer for intravenous ocrelizumab-treated patients than for placebo-treated patients (see Figure 2). Results for Study 3 are presented in Table 4 and Figure 2.

In the overall population in Study 3, the proportion of patients with 20 percent worsening of the timed 25-foot walk confirmed at 12 weeks was 49% in intravenous ocrelizumab-treated patients compared to 59% in placebo-treated patients (25% risk reduction).

In exploratory subgroup analyses of Study 3, the proportion of female patients with disability progression confirmed at 12 weeks after onset was similar in intravenous ocrelizumab-treated patients and placebo-treated patients (approximately 36% in each group). In male patients, the proportion of patients with disability progression confirmed at 12 weeks after onset was approximately 30% in intravenous ocrelizumab-treated patients and 43% in placebo-treated patients. Clinical and MRI endpoints that generally favored intravenous ocrelizumab numerically in the overall population, and that showed similar trends in both male and female patients, included annualized relapse rate, change in T2 lesion volume, and number of new or enlarging T2 lesions.
INTRODUCTION: Supraventricular tachycardia (SVT) can occur during treatment of an acute asthma exacerbation. There are, however, no data on the long-term outcomes of children who are diagnosed with both asthma and SVT. This study aims to analyze the impact of SVT in asthmatic children on mortality and/or cardiac arrest, hypothesizing asthmatic subjects with SVT have increased mortality and/or cardiac arrest compared to asthmatic subject with no-SVT.
METHODS: This was a retrospective cohort study, utilizing the TriNetX© electronic health record (EHR) database that included asthmatic subjects 2-18 years of age. The study population was divided into two groups (subjects with SVT diagnosis and no-SVT diagnosis). Data related to demographics, diagnostic, procedural, and medication codes were collected. The primary outcome was any death and/or cardiac arrest in a patient after the first asthma diagnosis date.
RESULTS: This study included 91,066 asthmatic subjects (244 [0.27%] with SVT and 90,822 [99.73%] with no-SVT). Multivariable logistic regression analysis demonstrated that after controlling for demographic and clinical features, the odds of all-cause death and/or cardiac arrest after the first reported asthma exacerbation was significantly higher in asthmatic children with SVT compared to no-SVT (odds ratio [OR]: 4.30, confidence interval [CI]: 2.50-7.39, p < .001).
CONCLUSIONS: Our large nationwide EHR study suggests that asthmatic pediatric patients with documented SVT diagnosis at any point in their EHR may be at increased risk of adverse health outcomes compared to no-SVT. Further studies are needed to determine the factors contributing to the increased risk of mortality and/or cardiac arrest in children with asthma and SVT.
Experimental group in Ⅱa (part one). It will be the dose B of SIBP-03. It will determine whether the dose B is the RP2D based on actual study results.
Traditional adhesive hydrogels perform well in tissue adhesion but they fail to prevent postoperative tissue adhesion. To address this challenge, a biodegradable Janus adhesive hydrogel (J-AH) was designed and fabricated by the assembly of three different functional layers including anti-adhesive layer, reinforceable layer, and wet tissue adhesive layer. Each layer of J-AH serves a specific function: the top zwitterionic polymeric anti-adhesive layer shows superior resistance to cell/protein and tissue adhesion; the middle poly(vinyl alcohol)/tannic acid reinforceable matrix layer endows the hydrogel with good mechanical toughness of ∼2.700 MJ/m3; the bottom poly(acrylic acid)/polyethyleneimine adhesive layer imparts tough adhesion (∼382.93 J/m2 of interfacial toughness) to wet tissues. In the rat liver and femoral injury models, J-AH could firmly adhere to the bleeding tissues to seal the wounds and exhibit impressive hemostatic efficiency. Moreover, in the in vivo adhesion/anti-adhesion assay of J-AH between the defected cecum and peritoneal walls, the top anti-adhesive layer can effectively inhibit undesired postoperative abdominal adhesion and inflammatory reaction. Therefore, this research may present a new strategy for the design of advanced bio-absorbable Janus adhesive hydrogels with multi-functions including tissue adhesion, anti-postoperative adhesion and biodegradation. STATEMENT OF SIGNIFICANCE: Despite many adhesive hydrogels with tough tissue adhesion capability have been reported, their proclivity for undesired postoperative adhesion remains a serious problem. The postoperative adhesion may lead to major complications and even endanger the lives of patients. The injectable hydrogels can cover the irregular wound and suppress the formation of postoperative adhesion. However, due to the lack of adhesive properties with tissue, it is difficult for the hydrogels to maintain on the wound surface, resulting in poor anti-postoperative adhesion effect. Herein, we design a Janus adhesive hydrogel (J-AH). J-AH integrates together robust wet tissue adhesion and anti-postoperative adhesion. Therefore, this research may present a new strategy for the design of advanced bio-absorbable Janus adhesive hydrogels.
A lipid mobilizer may be obtained by dialysing the plasma of stressed mammals and freeze drying the dialysate.  Specified nammals are rat, dog, man and preferably horse.  Specified stresses are subjection to sub-normal temperature above 0 DEG C., administration of a convulsant drug such as diisopropylfluorophosphate or cholic acid, injection of protamine, anti-kidney serum or preferably cortisone.  The lipid mobilizer may be dissolved in pyrogen-free aqueous medium for parenteral administration.  The lipid mobilizer has the property when injected into animals of producing hyperlipemia, hyperphagia and depleting fat deposits in the body.  It is a non-protein solid, freely soluble in water and physiological salt solution, less soluble in methanol and insoluble in 95 per cent ethanol or acetone, non-extractable by ether from acid or alkaline aqueous solutions, dialysable through semi-permeable membranes against water, comprising a low molecular weight polypeptide as the active ingredient, free of steroids and giving a positive ninhydrin reaction.
Subjects will receive a single oral dose of metformin on Days 1 and 10, a single dose of ASP015K on Day 3 and multiple doses of ASP015K once daily Day 5 to Day 11. Subjects will receive a single dose of metformin and ASP015K concurrently on Day 10.
1,132,576. X-ray contrast agents. MALLINCKRODT CHEMICAL WORKS. 26 Nov., 1965, No. 50458/65. Heading A5B. An X-ray contrast composition comprises BaSO 4  and a non-toxic fluidizing agent which is a water-dispersible colloidal anionic ether or ester derivative of a low molecular weight polymer glucan or a salt thereof (e.g. sodium CMC, sodium dextran sulphate or other starch derivatives), a 2% W/W aqueous solution of which at 25‹C has a viscosity not above 50 centipoises and which is present in an amount within the range 0.04 to 1.0 gm. per 100 gms. of BaSO 4 . Carrageenin and other conventional additives, e.g. polyhydric alcohols, wetting agents and antifoaming agents, may also be present. The compositions may be prepared dry and used for the extemporaneous preparation of aqueous suspensions for radiographic purposes.
The investigator will record the medical history of each patient and information such as age, body size (weight, height) and body mass index (BMI = kg / m \^ 2). Girls will also be given the time of appearance of menstruation, a factor that needs to be evaluated because the growth of the skeleton continues three years after its appearance. Patients will be subjected to Adam's Test, x-ray's and as well as lateral bending radiographs.In the first contact with each patient, will be evaluated bone density measured by DEXA as well as haematological testing including PTH, alkaline phosphatase (ALP), calcium (Ca), phosphorus( P ), Calcitonin and, of course, vitamin D (total and metabolite 25 (OH) D).

Each patient's follow-up will be completed in two years by a clinical examination every six months and a clinical, laboratory and radiological examination per year. Patients will be divided into two groups. In a group with patients with normal 25 (OH) D and in a second group with patients with low levels of 25 (OH) D. Members of the second group will receive substitution treatment with an appropriate formulation. The results will be collected and evaluated using statistical programme.
Approximately 150 active duty service members meeting DSM-5 criteria for PTSD and scoring 50 or above on the Clinician Administered PTSD Score for DSM-5 (CAPS-5) will be recruited for a prospective, randomized, double-blinded, controlled trial. Participants will be recruited via referral from other providers or self-referral from recruitment fliers. CAPS-5 is considered the gold-standard for PTSD symptom assessment in research. An initial PHQ-9,PCL-5, urine drug screen, and pregnancy test will be obtained at that visit as well. Qualifying participants will then meet with a prescriber, review informed consent, draw a number for randomization, and complete the SCID-5. The participant will then meet with the pharmacist who will dispense either venlafaxine XR or placebo. Randomization will have occurred before any participants have been recruited. Randomization will consist of use of a random number generator to generate 150 numbers. The pharmacist will secretly assign half of the numbers to treatment and half to control. Numbers generated will be written on slips of paper and placed in opaque envelopes then placed in a box. Participants will then draw their own numbers and inform the researchers of the number drawn. The titration schedule for the venlafaxine XR/placebo will be 3 days at 37.5mg, 7 days at 75mg, then increasing to 150mg. The participant will meet with the prescriber after 4 weeks at 150mg to determine if an increase to 225mg is warranted based on the participants DSM-5 PTSD symptoms. Meetings with a prescriber will then occur monthly throughout the study unless side effects or other concerns require more frequent follow up. Prescriber visits will be scheduled for 30 minutes, however, visits could be completed in as little as five minutes if the medication is working well with no side effects, blood pressure remains at baseline, the participant remains adherent to both medication and therapy, and the participant raises no concerns. Participants will meet with the pharmacist on a monthly basis for pill counts. EMDR sessions will occur weekly if possible and not any less than once every 2 weeks. Two sessions are allowed in 1 week if the participant anticipates going to the field or otherwise being unavailable for regular visits. All EMDR sessions will be recorded using a camcorder and the principal investigator will review 10% of all therapy sessions (a minimum of 1 session per participant) using a fidelity checklist. CAPS-5 assessments will be completed by an individual not involved in a participant's direct treatment and will be administered after completion of EMDR and again at 6 months from the date of his/her first therapy session. A urine drug screen will be ordered with each CAPS-5. Missing data/participant drop out will be handled using last object carried forward. Comparisons between interventions will be computed using a student's T-test for single comparisons between groups or ANOVA when multiple comparisons/time points are involved. If at any point a participant requests a record of treatment, a summary of care will be provided.
Healthy participants who participate in 1 study visit. The unhealthy participant will undergo one functional MRI before, during and after a NeuroGlove session.
<P>PROBLEM TO BE SOLVED: To provide a method for diagnosing tumor having GnRH receptor, and to provide a method for treating the tumor.  <P>SOLUTION: The use of GnRH agonist or GnRH antagonist for producing medicines for the treatments of tumors and/or Kaposi's sarcoma originated from brains and/or central nervous systems and/or meninges. A method for detecting tumors and/or Kaposi's sarcoma originated from brains and/or central nervous systems and/or meninges, and a kit for diagnosing the same are provided. A combination of melatonin or a melatonin analogue with GnRH agonist or GnRH antagonist is provided. The GnRH agonist or GnRH antagonist is combined with a cytotoxic substance and then used.  <P>COPYRIGHT: (C)2007,JPO&INPIT
INTRODUCTION: The antioxidant effects of vitamins may attenuate the oxidative stress on organs imposed by ischemia-reperfusion injury during the process of organ transplantation from brain-dead donors. Circulating levels of vitamins A, C, and E-α in donors after brain death and their relationships to donor demographics, management, organ utilization, and recipient outcomes are largely unknown.
METHODS: An observational, prospective, cohort study of 84 consecutive brain-dead organ donors managed at a single organ procurement recovery center was conducted. Vitamin levels were drawn immediately prior to procurement.
RESULTS: Levels of serum vitamins A and E-α and plasma vitamin C were below normal in 80%, 85%, and 92% of donors and deficient in 40%, 62%, and 63%, respectively. Vitamin C deficiency was associated with a longer time between death and specimen collection (P = .004). Death from head trauma and stroke were associated with lower levels of vitamin A than from anoxic causes (P = .003) and smokers had greater vitamin C deficiency (P = .03). During donor management, vitamin C deficiency was associated with longer vasopressor support (P = .03) and normal levels of vitamin E-α were associated with reaching a lower alanine transferase compared to those with subnormal levels (P < .05). Donors deficient in vitamin E-α were less likely to have a liver recovered for transplantation (P = .005). Vitamin levels were not associated with the recipient outcomes examined.
CONCLUSION: Circulating vitamins A, C, and E-α is profoundly low in brain-dead organ donors, associated with relevant demographic features of the donor, and may influence donor management and organ utilization.
BACKGROUND: Accurately predicting post-discharge mortality risk in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) remains a complex and critical challenge. The primary objective of this study was to develop and validate a robust risk prediction model to assess the 12-month and 24-month mortality risk in STEMI patients after hospital discharge.
METHODS: A retrospective study was conducted on 664 STEMI patients who underwent PPCI at Xiangtan Central Hospital Chest Pain Center between 2020 and 2022. The dataset was randomly divided into a training cohort (n = 464) and a validation cohort (n = 200) using a 7:3 ratio. The primary outcome was all-cause mortality following hospital discharge. The least absolute shrinkage and selection operator (LASSO) regression model was employed to identify the optimal predictive variables. Based on these variables, a regression model was constructed to determine the significant predictors of mortality. The performance of the model was evaluated using receiver operating characteristic (ROC) curve analysis and decision curve analysis (DCA).
RESULTS: The prognostic model was developed based on the LASSO regression results and further validated using the independent validation cohort. LASSO regression identified five important predictors: age, Killip classification, B-type natriuretic peptide precursor (NTpro-BNP), left ventricular ejection fraction (LVEF), and the usage of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (ACEI/ARB/ARNI). The Harrell's concordance index (C-index) for the training and validation cohorts were 0.863 (95% CI: 0.792-0.934) and 0.888 (95% CI: 0.821-0.955), respectively. The area under the curve (AUC) for the training cohort at 12 months and 24 months was 0.785 (95% CI: 0.771-0.948) and 0.812 (95% CI: 0.772-0.940), respectively, while the corresponding values for the validation cohort were 0.864 (95% CI: 0.604-0.965) and 0.845 (95% CI: 0.705-0.951). These results confirm the stability and predictive accuracy of our model, demonstrating its reliable discriminative ability for post-discharge all-cause mortality risk. DCA analysis exhibited favorable net benefit of the nomogram.
CONCLUSION: The developed nomogram shows potential as a tool for predicting post-discharge mortality in STEMI patients undergoing PPCI. However, its full utility awaits confirmation through broader external and temporal validation.
The invention relates to a vaccine which comprises an antigen and a lymphoid organ modifying agent. Suitable lymphoid organ modifying agents include, but are not limited to, 1,25-dihydroxy Vitamin D3, and Vitamin D3 derivatives which are capable of activating the intracellular Vitamin D3 receptor, all trans-retinoic acid, retinoic acid derivatives, retinol, retinol derivatives and glucocorticoid. The vaccine composition may further comprise an immune response augmenting agent. The immune response augmenting agent enhances T cell lymphokine production. Suitable immune response augmenting agents include, but are not limited to, DHEA and DHEA-derivatives. Examples of DHEA derivatives include DHEA-sulfate (DHEA-S), 16- alpha -bromo-DHEA, 7-oxo-DHEA, 16- alpha -bromo-DHEA-S, and 7-oxo-DHEA-S.
PURPOSE: To obtain the subject readily absorbable mineral effectively acting on the cell level in a target organ, by neutralizing a mineral salt of pentose or hexose carboxylic acid derivative with a specific amino acid. CONSTITUTION: This mineral is biologically available form is obtained by combining a mineral salt of pentose or hexose carboxylic acid derivative (e.g. zinc gluconate) with at least one kind of amino acid selected from the group consisting of alanine, valine, isoleucine, proline, glycine, serine, threonine, asparagine, glutamine, lysine, arginine and histidine in the molar ratio of (0.05:1.0) to (1.0:0.05), pref. (0.1:0.3) to (0.3:0.1) so as to be neutralized at pH6-8 (pref. pH6.5-7.5). The mineral to be used is e.g. zinc, calcium, iron, magnesium, manganese.
Patients assigned to this arm will receive an intravenous dose of tocilizumab. Patients weighing 75 kg or more will receive 600 mg. Those weighing less than 75 kg will receive 400 mg.
A pharmaceutical composition suitable for treatment of disorders of the oesophagus, especially those associated with reflux such as dyspepsia, oesophagitis and gastritis, comprises (a) 0.1-11% (by weight) of an alginate salt, most preferably sodium alginate; (b) 0.01-3.0% (by weight) of xanthan gum, carrageenan gum or mixtures thereof; and (c) 0.01-3.0% (by weight) of a glucomannan, a galactomannan or mixtures thereof. The preferred galactomannan is locust bean gum. The proportion of alginate salt added to the composition is chosen to ensure that, when the composition is prepared in the preferred aqueous liquid form, the viscosity of the composition remains in the range 1000 to 8000 mPa.s. which, in turn, ensures that the liquid composition obtained may be easily poured and dispensed in measurable volume amounts. The composition may also contain a source of carbon dioxide for, example sodium bicarbonate, which is released when the composition finally enters and contacts the acidic stomach environment. Any one of a range of pharmaceutically active compounds, such as cough suppressants or anti-ulcer drugs, may be included in the composition. The composition when applied in liquid form serves as a bioadhesive material which coats the mucosal surface of the oesophagus and thus provides a physical protection of the surface from reflux and also provides the means to deliver a pharmaceutically active agent to the surface.
FIELD: medicamentous preparations. SUBSTANCE: ointment may be used for treatment of purulent wounds, phlegmons, decubituses and other pathologies caused by reproduction of microorganisms strains in wounds. Ointment composition contains preparations of silver and base. Used as silver preparation is colloid atomic silver, and is 3-4 gel of polyethyleneoxide prepared by method of radiation joint. The components are used in the following ratio, mas. %; colloid silver, 0.07-0.48; polyvinylpirrolidon, 0.93-5.52; polyethyleneoxide gel, the balance. EFFECT: new bactericidal preparation accelerating wounds healing. 4 ex
All participants will get each of the 3 medicines at 3 different timepoints IcoSema - insulin icodec - semaglutide, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.